Work

Budget impact analysis of capivasertib as a second-line therapy for advanced breast cancer in the United States

Year: 2026

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2026.2691183

Authors: Trang Nguyen, Shweta Mital

Institution: University of Manitoba

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7165041337

FWCI:

Cites: 18

Cited by:

Related to: